Resumen de: US2023165493A1

A subcutaneous sensor for use with a continuous glucose monitor includes a reference electrode, a working electrode, and a composition for releasing nitric oxide (NO). The reference electrode includes a reference substrate and an ion limiting layer over the reference substrate. The working electrode includes a conductive substrate, an interference layer over the conductive substrate, an enzyme layer over the interference layer, and a glucose limiting layer. The enzyme layer has an enzyme for reacting with in-vivo glucose in body fluid of a patient. The glucose limiting layer is over the enzyme layer and limits an amount of the in-vivo glucose from the body fluid of the patient that passes to the enzyme layer. The composition for releasing nitric oxide (NO) includes a NO release compound, a hydrophilic material and a hydrophobic material. The composition is on the reference electrode.

Resumen de: US2023170936A1

Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are disclosed. In an embodiment, a method for transmitting data between a first communication device associated with an analyte sensor and a second communication device configured to provide user access to sensor-related information comprises: activating a transceiver of a first communication device associated with an analyte sensor at a first time; and establishing a two-way communication channel with the second communication device; wherein the activating comprises waking the transceiver from a low power sleep mode using a forced wakeup from the second communication device.

Resumen de: US2023170090A1

Methods and apparatus, including computer program products, are provided for processing analyte data. In some example implementations, a method may include generating glucose sensor data indicative of a host's glucose concentration using a glucose sensor; calculating a glycemic variability index (GVI) value based on the glucose sensor data; and providing output to a user responsive to the calculated glycemic variability index value. The GVI may be a ratio of a length of a line representative of the sensor data and an ideal length of the line. Related systems, methods, and articles of manufacture are also disclosed.

Resumen de: US2023166035A1

Automated glucose level control system that provide therapy to a subject, such as glucose control, are disclosed. The system generates dose control signals using control algorithms configured to autonomously determine doses of insulin to be infused into a subject. When the system determines that an initial dose control signal does not indicate health-appropriate therapy, the system can modify a manual therapy instruction and transmit an emergency dose control signal to the medicament pump. Disclosed systems and devices can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject. The system can generate a backup therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.

Resumen de: US2023165466A1

Disclosed embodiments include methods and systems including a receiver unit of a glucose monitoring system. The receiver unit is configured to receive a key associated with a transmitter unit that enables the receiver unit to identify the transmitter unit, initiate communication with the transmitter unit, access a communication key uniquely associated with the transmitter unit, and receive communication packets from the remote transmitter unit on a periodic basis including data indicative of a glucose level of a bodily fluid. The receiver unit is further configured to process the data determine the glucose level for display, output a numerical representation of the determined glucose level in a GUI, and transmit data indicative of the glucose level to a second receiver unit.

Resumen de: US2023165490A1

Disclosed herein are techniques related to automatic real-time meal detection. In some embodiments, the techniques involve obtaining a plurality of glucose concentration values and a plurality of plasma insulin concentration estimations, each glucose concentration value corresponding with a respective plasma insulin concentration estimation; generating an output based on applying a meal detection model to the plurality of glucose concentration values and the plurality of plasma insulin concentration estimations; and determining, based on the output, that a glucose concentration value of the plurality of glucose concentration values corresponds to an ongoing glycemic response to a meal.

Resumen de: WO2023096267A1

A device for estimating diabetic nephropathy according to one embodiment of the present disclosure comprises: at least one processor; and a memory electrically connected to the processor and for storing at least one code executed in the processor. The memory may store a code which, when executed by the processor, enables the processor to: confirm the demographic data, clinical data and diagnostic examination data of a subject; confirm the measurement dates of the diagnostic examination data; and estimate the occurrence and exacerbation of diabetic nephropathy of the subject by inputting the demographic data, clinical data, diagnostic examination data and time-series change data of the diagnostic examination data to a machine learning-based learning model.

Resumen de: US2023166033A1

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and/or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and/or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

Resumen de: US2023166037A1

Disclosed herein are systems and methods for automated insulin delivery that provide for adaptive closed loop control that can modify the stored basal profile used by the closed loop algorithm to better reflect the user's actual needs. Actual delivery rates calculated by the closed loop algorithm can be compared to the user's stored profile. If the differences between the actual delivery rates and the stored profile are statistically significant, the stored profile can be modified.

Resumen de: WO2023092908A1

An artificial pancreas control method, comprising: determining a change of blood glucose according to acquired blood glucose data; if the blood glucose presents a falling trend, determining whether a blood glucose lowering level exceeds a first threshold within a first set time before a current time, or determining whether a blood glucose level is lower than a second threshold at the current time or linearly predicting, along a blood glucose change curve, whether the blood glucose level is lower than the second threshold within a second set time after the current time, if yes, controlling to stop insulin infusion, until a blood glucose state is stable; and if the blood glucose presents a rising trend, determining whether the blood glucose level is greater than a third threshold at the current time or linearly predicting, along the blood glucose change curve, whether the blood glucose level is greater than the third threshold within the second set time after the current time, if yes, using a model prediction control algorithm to control insulin infusion. The artificial pancreas control method improves the safety of insulin infusion, reduces the number of operations of the model prediction control algorithm to the greatest extent, and optimizes the calculation process.

Resumen de: WO2023093457A1

A continuous glucose monitoring method and system, and a readable storage medium. The method comprises: acquiring interstitial fluid glucose signals (S11); and performing low-pass filtering deconvolution on the interstitial fluid glucose signals according to a difference in the rate of change in the interstitial fluid glucose signals by means of a low-pass filter model having a corresponding amplitude and a corresponding phase, so as to obtain a blood glucose signal (S12). That is, according to differences in the rate of change in interstitial fluid glucose signals, low-pass filter models having different amplitudes and phases are matched to perform calculation on the interstitial fluid glucose signals in segments to obtain more accurate blood glucose signals; thus, the problems of excessive delay caused by a filter and dynamic time delay and amplitude deviation caused by blood glucose and interstitial fluid glucose at different rates of change are solved.

Resumen de: US2023165534A1

Systems and methods for detecting noise episodes and processing analyte sensor data responsive thereto. In some embodiments, processing analyte sensor data includes filtering the sensor data to reduce or eliminate the effects of the noise episode on the signal.

Resumen de: WO2023095171A1

The present disclosure relates to a non-invasive sensing system (100) for measuring key body vitals. The system (100) includes a sensing device (102) to generate a pre-processed signal in response to the lights reflected by the fingertips of a user. The pre-processed signal is received by a client application (708) for extracting features using a pre-trained artificial intelligence (AI) based model to accurately measure at least six key body vitals including blood glucose, blood sugar (HBA1C), electrocardiogram (ECG), heart rate, blood oxygen level (SPo2), blood pressure, and body temperature. The system (100) also includes a user interface (706), of the client application (708), to receive a request for the measured key body vitals and to output the measured key body vitals.

Resumen de: WO2022020197A1

Disclosed are techniques and a device operable to determine a total amount of insulin delivered to the user over a predetermined time period. The total amount of insulin includes a total basal dosage delivered in basal dosages and a total bolus dosage delivered in bolus dosages over the predetermined time period. A proportion of the total amount of insulin delivered to the user provided via the total basal dosage amount over the predetermined time period is calculated. In response determining the proportion of the total amount of insulin attributed to the total basal dosage amount of insulin exceeds a threshold, an average basal dosage to be delivered within a subsequent time period that is approximately equal to the threshold may be determined. An instruction may be generated and output to deliver a modified basal dosage that substantially maintains the average basal dosage over the subsequent time period.

Resumen de: WO2023091915A1

The disclosed opto-enzymatic analyte physiological sensors exhibit improved bonding or adherence between at least two layers of the sensor, either directly or through an intermediate layer, which provides improved function of the sensor. In certain embodiments, there is bonding or adherence of the enzymatic hydrogel to the target analyte dependent oxygen sensing polymer matrix, either directly or through an intermediate barrier layer, such that changes in the partial pressure of oxygen in the enzymatic hydrogel matrix are rapidly reflected in the partial pressure of oxygen in the oxygen sensing matrix. The sensors provide an implantable, wearable, disposable and ideally low-cost way to continuously sense one or more analytes in the body, such as glucose.

Resumen de: US2023157566A1

Electrochemical Impedance Spectroscopy (EIS) is used in conjunction with continuous glucose monitors and continuous glucose monitoring (CGM) to enable in-vivo sensor calibration. gross (sensor) failure analysis, and intelligent sensor diagnostics and faith detection. An equivalent circuit model is defined, and circuit elements are used to characterize sensor behavior.

Resumen de: US2023157643A1

Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management.

Resumen de: US2023157598A1

A method includes monitoring, via a device including an electrochemical cell, an electrical current that is proportional to an impedance of the electrochemical cell, and responsive to determining that the electrical current satisfies a threshold, measuring, via the device, a plurality of impedances of the electrochemical cell corresponding to a plurality of frequencies. The method further includes determining a charge transfer conductance and a solution resistance based on the plurality of impedances at fewer than four of the corresponding plurality of frequencies and determining the presence of electrochemical interference based on the solution resistance and the charge transfer conductance. The method further includes outputting an alert based on the determination of the presence of electrochemical interference.

Resumen de: US2023157783A1

A computer-assisted medical device is configured and used to endoluminally navigate to a location in the gastrointestinal system and there treat certain body lumen wall areas while avoiding other body lumen wall areas. Embodiments ablate the inner mucosal layer and sub-mucosal nerve plexus of the stomach, duodenum and jejunum to effect treatment of insulin resistance and metabolic disorders, such as Type II diabetes (T2D), polycystic ovarian syndrome (PCOS), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), congestive heart failure (CHF) and obstructive sleep apnea (OSA). Various sensors are used to assist a clinical operator to navigate from the mouth through the pyloric sphincter and into and through the duodenum and/or jejunum. Various sensors are used to map and identify portions of the duodenum and/or jejunum. Various lumen wall ablation devices and methods are described. Various post-treatment assessments are described.

Resumen de: US2023158234A1

A method of determining initial insulin dosage range for patients with diabetes includes determining insulin dosage range based upon factors of estimated glomerular filtration rate (eGFR) and body mass index (BMI), and administering such dosage to the patient.

Resumen de: US2023158822A1

A method of fabricating metasurface on skin for blood glucose detection, which relates to a flexible wearable electronic technology in healthcare. The blood glucose detectioncomprises: designing metasurface with a resonant ring structure cell, and building a model by simulating a relationship between blood glucose concentration and electromagnetic absorption property of the metasurface; preparing the metasurface on the skin; scanning the metasurface on the skin under different frequencies electromagnetic wave and acquiring a relationship curve between S-11 parameter and frequency; the change of blood glucose concentration is determined according to the resonant peak frequency shift in the relationship curve based on the model. It realizes the electromagnetic wave metasurface with a good skin biocompatibility, a stable electromagnetic property and a high glucose detection accuracy is directly structured on the skin, moreover, it can directly measure human blood glucose concentration without sampling human blood, realizing real non-invasive human blood glucose detection.

Resumen de: WO2023087672A1

A blood glucose prediction method and device based on optical signal features and metabolic thermal features. The method comprises: acquiring first calibrated blood glucose data (1); collecting and generating first, second, third and fourth optical signals (2); collecting and generating first, second, third, fourth, fifth, sixth and seventh metabolic thermal signals (3); extracting and normalizing human optical signal features to generate first, second and third optical feature data groups (4); extracting and normalizing ambient light signal features to generate fourth optical feature data (5); extracting and normalizing metabolic thermal features to generate first, second, third, fourth, fifth, sixth and seventh metabolic thermal feature data (6); performing feature fusion to generate a first feature vector (7); predicting, on the basis of the floating blood glucose prediction model, floating blood glucose values to generate first floating blood glucose data (8); and generating first predicted blood glucose data according to the sum of the first calibrated blood glucose data and the first floating blood glucose data (9). The blood glucose prediction method and device based on optical signal features and metabolic thermal features can be used to provide a non-invasive blood glucose measurement mechanism.

Resumen de: WO2023088265A1

A blood sugar level obtaining apparatus, a blood sugar level measurement apparatus, and a method. The blood sugar level obtaining apparatus comprises a pressure obtaining module (110), a spectral intensity obtaining module (120), and a result obtaining module (130); the pressure obtaining module (110) is used for obtaining pressure data of a part under test of a user acting on a measurement board in a measurement apparatus; the spectral intensity obtaining module (120) is used for obtaining spectral signal intensity acquired when a spectrometer irradiates the measurement board, wherein the spectral signal intensity and the pressure data are obtained in a same time period; the result obtaining module (130) is used for obtaining a blood sugar level measurement result on the basis of the pressure data and the spectral signal intensity.

Resumen de: GB2613032A

A system and method of calibrating a model used in a device for non-invasive in vivo measurement of an analyte concentration using Raman spectroscopy. The device comprises an optical source for providing an optical signal and an optical detector to receive a Raman scattered optical output. The method (Fig.2) comprises, in response to the laser source being directed to a user’s skin 213, gathering Raman scattered radiation from the user’s skin and based on that, calibrating the model based on reference data and the received Raman spectra over an extended period of days. Once the model is calibrated, storing the model for use. The calibration period can be 14 days or 20 days or between 20 and 28 days. The method may comprise receiving reference data from an invasive blood glucose monitoring device.

Resumen de: WO2022013140A1

A continuous glucose monitoring (CGM) system is configured to detect a reinserted CGM sensor. The system reads a CGM sensor identifier stored in a CGM sensor unit memory in response to insertion of a CGM sensor into the skin of user. The system compares the identifier to any previously-stored identifiers of previously-inserted CGM sensors. If the identifier does not match a previously-stored identifier, indicating a newly-inserted sensor, the identifier is stored and CGM may begin. If the identifier matches a previously- stored identifier, indicating a reinserted sensor, a usage limit corresponding to the stored identifier of the reinserted sensor is then checked to determine whether it has been met. If it has, CGM is halted. If it has not, CGM may continue with the reinserted CGM sensor. Methods of detecting reinsertion and usage limits of a CGM sensor are also provided, as are other aspects.